Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma

This study is testing a combination of immunotherapy (adebrelimab) plus chemotherapy (etoposide and cisplatin) given before surgery for a rare and aggressive type of bladder cancer called neuroendocrine carcinoma. Researchers want to see if this pre-surgery (neoadjuvant) treatment can shrink the tumor and improve surgical outcomes. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with invasive neuroendocrine carcinoma of the bladder, with neuroendocrine cells making up more than 50% of the tumor - Your cancer is localized (T1–T4a, N0 or limited lymph node involvement, no distant spread) - Your overall health and organ function are adequate (ECOG 0–2) - Your expected survival is longer than 3 months **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have significant heart, liver, or kidney problems - You have active autoimmune disease - You are pregnant or breastfeeding - You have previously received chemotherapy or immunotherapy for this cancer Talk to your doctor to see if this trial is right for you.